Zydus Lifesciences Limited — Celecoxib Exporter Profile
Indian Pharmaceutical Exporter · #7 for Celecoxib · $3.6M export value · DGFT Verified
Zydus Lifesciences Limited is the #7 Indian exporter of Celecoxib with $3.6M in export value and 149 verified shipments. Zydus Lifesciences Limited holds a 2.7% market share in Celecoxib exports across 15 countries. The company exports 81 pharmaceutical products worth $346.3M across 25 therapeutic categories.
Zydus Lifesciences Limited — Celecoxib Export Profile: Buyers & Destinations
Where Does Zydus Lifesciences Limited Export Celecoxib?
| Country | Value | Shipments | Share |
|---|---|---|---|
| SRI LANKA | $1.1M | 46 | 41.2% |
| KENYA | $507.8K | 23 | 18.3% |
| THAILAND | $387.6K | 17 | 14.0% |
| SPAIN | $218.0K | 10 | 7.9% |
| UGANDA | $159.3K | 7 | 5.7% |
| BRAZIL | $133.4K | 13 | 4.8% |
| MAURITIUS | $46.1K | 9 | 1.7% |
| FRANCE | $44.6K | 6 | 1.6% |
| YEMEN, DEMOCRATIC | $37.1K | 6 | 1.3% |
| SOUTH AFRICA | $36.9K | 2 | 1.3% |
Zydus Lifesciences Limited exports Celecoxib to 15 countries. The largest destination is SRI LANKA accounting for 41.2% of Zydus Lifesciences Limited's Celecoxib shipments, followed by KENYA (18.3%) and THAILAND (14.0%). These destinations reflect Zydus Lifesciences Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Celecoxib from Zydus Lifesciences Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| SUNSHINE HEALTHCARE LANKA LIMITED | SRI LANKA | $808.0K | 28 |
| ABACUS PHARMA (AFRICA) LTD | UGANDA | $469.0K | 20 |
| STATE PHARMACEUTICALS | SRI LANKA | $313.9K | 15 |
| PHARMALAND (1982) CO. LTD | THAILAND | $271.6K | 12 |
| ZYDUS NIKKHO FARMACEUTICA LTDA | BRAZIL | $133.4K | 13 |
| LABORATORIOS COMBIX SLU | SPAIN | $68.4K | 2 |
| ABACUS PHARMA (AFRICA) LTD. | UGANDA | $65.6K | 3 |
| PHARMALAND (1982) CO.LTD | THAILAND | $60.7K | 2 |
| DHL GLOBAL FORWARDING (SPAIN) | SPAIN | $50.0K | 1 |
| DHL GLOBAL FORWARDING SPAIN | SPAIN | $50.0K | 1 |
Zydus Lifesciences Limited supplies Celecoxib to 30 buyers globally. The largest buyer is SUNSHINE HEALTHCARE LANKA LIMITED (SRI LANKA), followed by ABACUS PHARMA (AFRICA) LTD (UGANDA) and STATE PHARMACEUTICALS (SRI LANKA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Celecoxib Export Value and How Much Does Zydus Lifesciences Limited Contribute?
India exported $62.9M worth of Celecoxib through 4,880 shipments from 326 suppliers to 112 countries, serving 781 buyers globally. Zydus Lifesciences Limited contributes $3.6M to this total, accounting for 2.7% of India's Celecoxib exports. Zydus Lifesciences Limited ships Celecoxib to 15 countries through 30 buyers.
What Is the Average Shipment Value for Zydus Lifesciences Limited's Celecoxib Exports?
Zydus Lifesciences Limited's average Celecoxib shipment value is $23.9K per consignment, based on 149 shipments totaling $3.6M. The largest destination is SRI LANKA (41.2% of Zydus Lifesciences Limited's Celecoxib exports).
How Does Zydus Lifesciences Limited Compare to Other Indian Celecoxib Exporters?
Zydus Lifesciences Limited ranks #7 among 326 Indian Celecoxib exporters with a 2.7% market share. The top 3 exporters are ALEMBIC PHARMACEUTICALS LIMITED ($12.2M), CIPLA LIMITED ($12.2M), MACLEODS PHARMACEUTICALS LTD ($9.2M). Zydus Lifesciences Limited processed 149 shipments to 15 destination countries.
What Celecoxib Formulations Does Zydus Lifesciences Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| ZYCEL 200MG CAPSULES (CELECOXIB) 10X10 | $427.3K | 14 |
| ZYCEL 200MG CAPSULES(CELECOXIB)(10X10) | $249.4K | 6 |
| ZYCEL 100MG CAPSULES(CELECOXIB)(10X10) | $147.1K | 7 |
| ZYCEL 100MG CAPSULES (CELECOXIB) 10X10 | $128.8K | 11 |
| CELECOXIB COMBIX 200MG CAPSULES | $68.4K | 2 |
| CELECOXIB CAPSULES 100MG (ZYCEL 100) (CE | $64.0K | 2 |
| ZYCEL 200MG CAPSULES (CELECOXIB) 10X1X10 | $60.7K | 2 |
| ZYCEL 200 CAPSULES (CELECOXIB) PACK OF 10X1X10 | $60.3K | 2 |
| CELECOXIB CAPSULES 100MG (CELECOXIB 100MG) 10X10 UNDER LUT NO.AD300324000860V DATED 21.03.2024 VALID UP TO 31.03.2025 | $60.1K | 4 |
| ZYCEL 100 (CELECOXIB CAPS) 10X10 SHIPMENT UNDER LUT No.AD300324000860V Dated 21.03.2024 valid up to 31.03.2025 | $57.0K | 2 |
Zydus Lifesciences Limited exports 71 distinct Celecoxib formulations including tablets, capsules, syrups, and combination drugs. The top formulation is ZYCEL 200MG CAPSULES (CELECOXIB) 10X10 with 14 shipments worth $427.3K.
How Does Zydus Lifesciences Limited Compare to Nearest Celecoxib Exporters?
Exporters ranked immediately above and below #7 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | MACLEODS PHARMACEUTICALS LTD | $9.2M | 184 | 21 | $50.0K |
| 5 | MICRO LABS LIMITED | $6.8M | 201 | 19 | $33.8K |
| 7 | ZYDUS LIFESCIENCES LIMITED ★ | $3.6M | 149 | 15 | $23.9K |
| 1 | UMEDICA LABORATORIES PRIVATE LIMITED | $3.3M | 65 | 2 | $50.0K |
| 9 | APOTEX RESEARCH PRIVATE LIMITED | $3.2M | 77 | 3 | $41.1K |
Zydus Lifesciences Limited ranks #7 among 326 Indian Celecoxib exporters. Average shipment value of $23.9K compared to the market average of $192.8K. The closest competitors by value are MACLEODS PHARMACEUTICALS LTD and MICRO LABS LIMITED.
Which Indian Ports Ship Celecoxib Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 544 | 11.1% |
| DELHI AIR CARGO ACC (INDEL4) | 475 | 9.7% |
| SAHAR AIR CARGO ACC (INBOM4) | 433 | 8.9% |
| SAHAR AIR | 323 | 6.6% |
| JNPT/ NHAVA SHEVA SEA | 305 | 6.3% |
| DELHI AIR | 256 | 5.2% |
| JNPT | 216 | 4.4% |
| MUNDRA SEA | 196 | 4.0% |
What Other Analgesics & Antipyretics Products Does Zydus Lifesciences Limited Export?
Zydus Lifesciences Limited also exports these analgesics & antipyretics products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Zydus Lifesciences Limited's Celecoxib Exports
Zydus Lifesciences's export operations are influenced by various geopolitical factors. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, increasing shipping costs and transit times for Indian exporters. This situation necessitates strategic logistics planning to mitigate potential delays and cost escalations.
Conversely, U.S.-China trade tensions have opened opportunities for Indian pharmaceutical companies like Zydus to capture a larger share of the U.S. market, as American importers seek alternative suppliers. Zydus's recent FDA approvals, including Niacin ER Tablets and Leuprolide Acetate injection, position the company to capitalize on this shift. (ainvest.com)
In the European Union, compliance with the Falsified Medicines Directive (FMD) is crucial for market access. Zydus's proactive measures to align with these regulations enhance its credibility and competitiveness in the EU market. However, the ongoing Israel-Iran conflict poses risks to Middle East trade routes, potentially affecting Zydus's operations in that region.
Zydus Lifesciences Limited — Regulatory Compliance & Quality Standards
Maintaining stringent quality standards is paramount for Zydus Lifesciences. In October 2025, the company received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the U.S. FDA for its Baddi manufacturing facility, indicating compliance with regulatory standards. (bajajbroking.in) Similarly, the Ahmedabad SEZ-II facility received a clean USFDA report in November 2025, further affirming the company's commitment to quality. (bajajbroking.in)
These regulatory approvals are critical, as non-compliance can lead to import bans and reputational damage. Zydus's adherence to Good Manufacturing Practices (GMP) and proactive engagement with regulatory bodies underscore its dedication to maintaining high-quality standards across its operations.
About Zydus Lifesciences Limited
Zydus Lifesciences Limited exports 81 products worth $346.3M. Beyond Celecoxib, top products include Losartan, Carvedilol, Iron, Mesalamine, Omeprazole. View the complete Zydus Lifesciences Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Celecoxib — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Celecoxib shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Zydus Lifesciences Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 149 individual customs records matching Zydus Lifesciences Limited exporting Celecoxib, covering 71 formulations to 15 countries via 30 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 112+ countries, 781+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Celecoxib Export Data from Zydus Lifesciences Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Zydus Lifesciences Limited's Celecoxib exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Zydus Lifesciences Limited
Full Company Profile →
81 products · $346.3M total trade · 25 categories
Celecoxib Stats
Company Overview
Top Products by Zydus Lifesciences Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Zydus Lifesciences Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Celecoxib. For current shipment-level data, contact TransData Nexus.